Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 1

Status

Recruiting 4

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 4

Sponsor

Cancer Type

Breast 81CNS 16Gynecologic 15Genitourinary 10Sarcoma 8Gastrointestinal 6Tumor-Agnostic 4Thoracic 4Head & Neck 2Plasma cell 1Other solid neoplasm 1Other neoplasm 1NET 1Lymphoid 1Endocrine 1

Conditions

Neoplasms 2Neoplasm Metastasis 2

Interventions

pembrolizumab 56Specimen Handling 28Biopsy 27Magnetic Resonance Spectroscopy 26Paclitaxel 22Blood Specimen Collection 21Nivolumab 20atezolizumab 18Standard of Care 18Carboplatin 18Surveys and Questionnaires 17Bevacizumab 17Oxaliplatin 13Fluorouracil 13Cisplatin 13Radiotherapy 12Radiosurgery 12Cyclophosphamide 12Pemetrexed 11Leucovorin 11Irinotecan 10Gemcitabine 10Docetaxel 10Capecitabine 10trastuzumab deruxtecan 8olaparib 8Taxes 8Ipilimumab 8durvalumab 7Trastuzumab 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
abemaciclib × Tumor-Agnostic × 1 year × Clear all
NCT04802759 2026-05-11

A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer

Hoffmann-La Roche

Phase 1/2 Recruiting
316 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT03310879 2026-04-29

Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-Type Cyclins or Amplification of CDK4 or CDK6

Dana-Farber Cancer Institute

Phase 2 Recruiting
38 enrolled
Tumor-Agnostic

Neoplasms

NCT05999994 2026-03-27

CAMPFIRE

Eli Lilly and Company

Phase 2 Recruiting
105 enrolled
Tumor-Agnostic

Neoplasms

NCT05933395 2026-01-20

GERTRUDE

Dartmouth-Hitchcock Medical Center

Phase 2 Recruiting
135 enrolled
Tumor-Agnostic

Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡